Compare VTOL & OLMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VTOL | OLMA |
|---|---|---|
| Founded | 1948 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Transportation Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.4B |
| IPO Year | 2011 | 2020 |
| Metric | VTOL | OLMA |
|---|---|---|
| Price | $41.68 | $13.02 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 10 |
| Target Price | ★ $58.00 | $44.89 |
| AVG Volume (30 Days) | 191.9K | ★ 940.6K |
| Earning Date | 05-05-2026 | 05-08-2026 |
| Dividend Yield | ★ 1.02% | N/A |
| EPS Growth | ★ 34.58 | 15.00 |
| EPS | ★ 0.44 | N/A |
| Revenue | ★ $1,490,512,000.00 | N/A |
| Revenue This Year | $11.64 | N/A |
| Revenue Next Year | $5.59 | N/A |
| P/E Ratio | $95.52 | ★ N/A |
| Revenue Growth | ★ 5.30 | N/A |
| 52 Week Low | $29.26 | $3.89 |
| 52 Week High | $50.38 | $36.26 |
| Indicator | VTOL | OLMA |
|---|---|---|
| Relative Strength Index (RSI) | 34.37 | 37.44 |
| Support Level | $35.98 | $12.87 |
| Resistance Level | $42.44 | $17.23 |
| Average True Range (ATR) | 1.28 | 0.87 |
| MACD | -0.02 | -0.02 |
| Stochastic Oscillator | 8.30 | 18.78 |
Bristow Group Inc is the provider of vertical flight solutions. The group provides aviation services to a broad base of offshore energy companies and government entities. Its business comprises three reportable segments: Offshore Energy Services, Government Services, and Other Services. Its customers are in the UK, Norway, the USA, Nigeria, and Others. The offshore energy customers use services to transport personnel to, from and between offshore energy installations. The majority of revenue is generated from Offshore Energy Services.
Olema Pharmaceuticals inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of next generation targeted therapies for women's cancers. Its therapies offer the potential to improve outcomes for women living with cancer. The company has completed discovery and preclinical studies of OP-1250. OP-3136 is another drug candidate in the company's product pipeline.